Arcellx is developing a new paradigm to revolutionize cell therapy. Current engineered immune cell therapies often target tumors through a mono-specific receptor that is constitutively expressed and active. In contrast, Arcellx has developed Antigen Receptor Complex T cells (ARC-T) that are readily silenced, activated, and reprogrammed in vivo by administration of a tumor-targeting antigen protein called a sparX. Arcellx’s platform aims to achieve enhanced SAFETY, improved EFFICACY, steamlined MANUFACTURING, and expanded UTILITY (target solid tumors and autoimmune indications). Arcellx has just started to come out of stealth mode and is backed by tier one investors composed of NEA, Novo, SR One, and Takeda Ventures.
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.